Humira

Humira. It is a biologic medication belonging to the class of tumor necrosis factor inhibitors, specifically a monoclonal antibody designed to target and neutralize tumor necrosis factor alpha. Developed by the biotechnology company AbbVie, it is administered via subcutaneous injection and has become one of the world's best-selling pharmaceuticals. Its approval by the U.S. Food and Drug Administration in 2002 marked a significant advancement in the treatment of several chronic inflammatory conditions.

Medical uses

Humira is indicated for a wide range of autoimmune diseases characterized by excessive tumor necrosis factor alpha activity. Its primary uses include the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It is also approved for managing ulcerative colitis, chronic plaque psoriasis, and hidradenitis suppurativa. In pediatric populations, it is used for polyarticular juvenile idiopathic arthritis. The medication is often prescribed when conventional therapies, such as methotrexate or other disease-modifying antirheumatic drugs, have proven inadequate. Clinical trials conducted at institutions like the Mayo Clinic and Cleveland Clinic have demonstrated its efficacy in reducing disease activity and improving quality of life.

Adverse effects

As a potent immunosuppressant, Humira carries a risk of serious and sometimes fatal adverse effects. The most significant concerns include an increased susceptibility to serious infections, such as tuberculosis, invasive fungal infections, and sepsis. There is an elevated risk for certain malignancies, particularly lymphoma and skin cancer. Other potential adverse reactions include hepatitis B virus reactivation, demyelinating diseases like multiple sclerosis, and hematologic abnormalities such as pancytopenia. Common injection-site reactions include erythema, itching, and pain. Patients are typically monitored by specialists at centers like Johns Hopkins Hospital for these potential complications.

Mechanism of action

Humira functions as a fully human immunoglobulin G1 monoclonal antibody that binds with high affinity and specificity to soluble and membrane-bound tumor necrosis factor alpha. By binding to this cytokine, it blocks its interaction with the p55 and p75 cell surface TNF receptors, thereby inhibiting the pro-inflammatory signaling cascade. This action reduces the recruitment of inflammatory cells, such as neutrophils and eosinophils, to sites of inflammation and decreases the production of other inflammatory mediators like interleukin-6 and C-reactive protein. The drug's development was based on research from scientists at Cambridge Antibody Technology and the University of Oxford.

History and society

The development of Humira originated from a collaboration between BASF subsidiary Knoll Pharmaceuticals and Cambridge Antibody Technology, utilizing phage display technology. After Abbott Laboratories acquired Knoll, the drug was brought to market, with the U.S. Food and Drug Administration granting approval in December 2002 for rheumatoid arthritis. Its subsequent approval for Crohn's disease by the European Medicines Agency expanded its global reach. Humira's patent protection, particularly in the United States, became a subject of extensive legal and political debate, involving entities like the U.S. Congress and the Patent Trial and Appeal Board. Its immense commercial success has significantly influenced the business strategies of AbbVie and the broader biopharmaceutical industry.

Biosimilars

With the expiration of key patents for Humira, numerous biosimilar versions have been developed and approved globally. In the European Union, biosimilars from companies like Amgen (Amjevita), Samsung Bioepis (Imraldi), and Novartis subsidiary Sandoz (Hyrimoz) have been marketed since 2018. The U.S. Food and Drug Administration began approving biosimilars, including Cyltezo from Boehringer Ingelheim and Hadlima from Organon & Co., with many launching in 2023. The introduction of biosimilars, supported by studies from the FDA Center for Drug Evaluation and Research, is expected to increase market competition and reduce healthcare costs, impacting systems like the National Health Service in the United Kingdom.

Category:Monoclonal antibodies Category:Immunosuppressive drugs Category:AbbVie